Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Dynasty Wealth Management LLC

Dynasty Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 301.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 4,444 shares of the medical research company's stock after acquiring an additional 3,337 shares during the period. Dynasty Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $2,211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $25,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. VSM Wealth Advisory LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $36,000. Navigoe LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $37,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $8.97 during mid-day trading on Thursday, hitting $425.28. The company's stock had a trading volume of 2,494,559 shares, compared to its average volume of 2,017,984. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $409.84 and a 200 day simple moving average of $474.37. The firm has a market capitalization of $160.54 billion, a P/E ratio of 24.94, a P/E/G ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.11 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TMO. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research note on Friday, July 11th. Finally, Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $600.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.